In NSCLC, 3.6% (5 of 139) of hotspot alterations associated with on-label matched therapies, which included BRAF V600E, EGFR alterations, ERBB2 alterations, and KRAS G12C, were detected at a VAF <5%. Here, ERBB2 is linked to non-small cell lung carcinoma.